Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Allergy Therapeutics ( (GB:AGY) ) is now available.
Allergy Therapeutics has reported an internal reorganisation within major shareholder ZQ Group, which transferred most of the company’s shares from SkyGem Acquisition to SkyGem International Holdings without changing ultimate beneficial ownership. The restructuring is intended to optimise ZQ’s holding structure in Allergy Therapeutics and clarifies the distribution of shares among related entities.
Separately, SkyGem International Holdings placed 209.6 million Allergy Therapeutics shares with four investors at an average price of 10 pence, with the paper-form shares locked out of AIM trading for 12 months. The placement aims to broaden and optimise the shareholder base ahead of a potential dual listing in Hong Kong, leaving ZQ Capital and associated entities controlling 60.5% of the company’s issued share capital and reinforcing their influence over its strategic direction.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £11.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The score is driven primarily by very weak financial performance (declining revenue, large losses, negative cash flows, and negative equity). Technicals are mixed with oversold signals but still negative momentum, and valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a UK-headquartered international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders. It develops and sells aluminium-free allergy immunotherapies with potential disease-modifying effects, marketing proprietary and third-party products across nine major European countries and through distributors in a further ten markets.
Average Trading Volume: 296,263
Technical Sentiment Signal: Buy
Current Market Cap: £728.2M
For detailed information about AGY stock, go to TipRanks’ Stock Analysis page.